Actelion receives Canada approval for Uptravi

[January 26, 2016]  ZURICH (Reuters) - Actelion Ltd, Europe's biggest biotech firm, said on Tuesday that Health Canada had granted a notice of compliance for Uptravi, a new pulmonary arterial hypertension medicine.

The approval is "a major milestone", Chief Executive Jean-Paul Clozel said in a statement, adding that the company is working to make the drug available to patients in Canada "as soon as possible".

Analysts have said Uptravi could reap more than $1 billion in global sales annually at its peak.

(Reporting by Joshua Franklin; editing by Brenna Hughes Neghaiwi)

[© 2016 Thomson Reuters. All rights reserved.]

Copyright 2016 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.